Medical Affairs 2030 - Charting the Strategic Evolution

Medical affairs is poised for a transformative evolution by 2030, becoming a cornerstone of the pharmaceutical industry.

Transitioning from a support function to a strategic leadership role alongside R&D and commercial teams, medical affairs' evolution is driven by the integration of digital technologies like AI and telehealth. Furthermore, medical affairs will focus on patient-centric strategies, representing patient voices to ensure treatments meet their needs.

FirstWord spoke to Samuel Dyer, medical affairs consultant and CEO of the Medical Science Liaison (MSL) Society, about the role of patient-centric approaches and RWE in the evolution of medical affairs.

Key Questions Answered:

• How do you see the role of medical affairs evolving by 2030?
• What impact do you think digital technologies, such as AI and telehealth, will have on medical affairs?
• How will medical affairs enhance its focus on patient-centric care in the coming years?
• What role will RWE play in the future of medical affairs, and how will it influence clinical decision making?
• How do you foresee the collaboration between medical affairs and other departments changing?
• What changes do you anticipate in the regulatory landscape, and how will medical affairs adapt?
• What new skills and competencies will be essential for medical affairs professionals in the future?
• How do you think the impact of medical affairs activities will be measured and demonstrated in the future?
• What are the biggest challenges and opportunities you foresee for medical affairs over the next decade?
• How will medical affairs drive innovation and adapt to the rapidly changing healthcare environment?

Methodology

Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.